SCHEMBL30744262

SCHEMBL30744262

CCCNCCCNCCCCNCCCNCCC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.69
ALDH1A1 P00352 1/20 0.69
CYP2C19 P33261 3/20 0.65
CYP1A2 P05177 2/20 0.65
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
GLA P06280 1/20 0.59
PAOX Q6QHF9 1/20 0.56
ADH1B P00325 2/20 0.45
ADH1A P07327 2/20 0.45
ADH7 P40394 2/20 0.45
CA12 O43570 2/20 0.44
CA2 P00918 2/20 0.44
CA4 P22748 2/20 0.44
CA6 P23280 2/20 0.44
CA5A P35218 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
CA5B Q9Y2D0 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7513630 1.00 TSHR (0.69) TSHRALDH1A1CYP2C19CYP1A2MEN1
SCHEMBL2639821 0.97 TSHR (0.65) TSHRALDH1A1CYP2C19CYP1A2MEN1
SCHEMBL8850864 0.97 TSHR (0.65) TSHRALDH1A1CYP2C19CYP1A2MEN1
SCHEMBL2905152 0.96 CYP2C19 (0.62) TSHRALDH1A1CYP2C19CYP1A2MEN1
SCHEMBL1247661 0.96 TSHR (0.73) TSHRALDH1A1CYP2C19CYP1A2MEN1
SCHEMBL1276412 0.96 CYP2C19 (0.62) TSHRALDH1A1CYP2C19CYP1A2MEN1
SCHEMBL21686603 0.94 TSHR (0.81) TSHRALDH1A1CYP2C19CYP1A2MEN1
Hydrochloric Acid SCHEMBL8011029 0.94 TSHR (0.61) TSHRALDH1A1CYP2C19CYP1A2MEN1
SCHEMBL10704190 0.93 CYP2C19 (0.59) TSHRALDH1A1CYP2C19CYP1A2MEN1
SCHEMBL1781797 0.93 TSHR (0.69) TSHRALDH1A1CYP2C19CYP1A2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014859-A1 OPERATION CONTROL METHOD, OPERATION CONTROL SYSTEM, AND OPERATION CONTROL PROGRAM YANMAR HOLDINGS CO LTD (JP) 2026-01-15 US disclosed
US-12441183-B2 Operation control method, operation control system, and operation control program Yanmar Holdings Co., Ltd. (JP) 2025-10-14 US disclosed
US-12415835-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-16 US disclosed
CN-118778624-A Operation control method, operation control system, and operation control program 洋马控股株式会社 2024-10-15 CN disclosed
US-20240336137-A1 OPERATION CONTROL METHOD, OPERATION CONTROL SYSTEM, AND OPERATION CONTROL PROGRAM Yanmar Holdings Co., Ltd. (JP) 2024-10-10 US disclosed
EP-4442524-A1 OPERATION CONTROL METHOD, OPERATION CONTROL SYSTEM, AND OPERATION CONTROL PROGRAM Yanmar Holdings Co., Ltd. (JP) 2024-10-09 EP disclosed
US-20240196775-A1 Operation Control Method, Operation Control System, And Operation Control Program Yanmar Holdings Co., Ltd. (JP) 2024-06-20 US disclosed
US-20240196782-A1 Operation Control Method, Operation Control System, And Operation Control Program Yanmar Holdings Co., Ltd. (JP) 2024-06-20 US disclosed
EP-4385300-A1 OPERATION CONTROL METHOD, OPERATION CONTROL SYSTEM, AND OPERATION CONTROL PROGRAM Yanmar Holdings Co., Ltd. (JP) 2024-06-19 EP disclosed
EP-4385297-A2 OPERATION CONTROL METHOD, OPERATION CONTROL SYSTEM, AND OPERATION CONTROL PROGRAM Yanmar Holdings Co., Ltd. (JP) 2024-06-19 EP disclosed
CN-118210331-A Operation control method, operation control system, and operation control program 洋马控股株式会社 2024-06-18 CN disclosed
CN-118210330-A Operation control method, operation control system, and operation control program 洋马控股株式会社 2024-06-18 CN disclosed
US-11891457-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891457-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R TSHR 1056/4885ALDH1A1 4857/4885CYP2C19 3767/4885
US-20260014859-A1 OPERATION CONTROL METHOD, OPERATION CONTROL SYSTEM, AND OPERATION CONTROL PROGRAM APP, BACE2, APH1B TSHR 2495/4885ALDH1A1 4333/4885CYP2C19 1127/4885
US-12415835-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R TSHR 1056/4885ALDH1A1 4857/4885CYP2C19 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.